Goldman Sachs Group Inc Oramed Pharmaceuticals Inc. Transaction History

Goldman Sachs Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 14, 2024	BUY	$2.51 - $3.55 $385,581 - $545,343	153,618 New	153,618 $400,000
Q3 2023 Nov 14, 2023	BUY	$2.51 - $3.55 $157,384 - $222,595	62,703 Added 68.97%	153,618 $400,000
Q2 2023 May 14, 2024	SELL	$2.12 - $4.47 $21,282 - $44,874	-10,039 Reduced 9.94%	90,915 $325,000
Q2 2023 Aug 14, 2023	SELL	$2.12 - $4.47 $21,282 - $44,874	-10,039 Reduced 9.94%	90,915 $325,000
Q1 2023 May 14, 2024	BUY	$1.93 - $13.1 $162,982 - $1.11 Million	84,447 Added 511.58%	100,954 $220,000
Q1 2023 May 11, 2023	BUY	$1.93 - $13.1 $162,982 - $1.11 Million	84,447 Added 511.58%	100,954 $220,000
Q4 2022 May 14, 2024	SELL	$5.88 - $12.03 $225,762 - $461,891	-38,395 Reduced 69.93%	16,507 $198,000
Q4 2022 Feb 13, 2023	SELL	$5.88 - $12.03 $225,762 - $461,891	-38,395 Reduced 69.93%	16,507 $198,000
Q3 2022 May 14, 2024	BUY	$4.6 - $9.91 $122,079 - $263,001	26,539 Added 93.57%	54,902 $355,000
Q3 2022 Nov 10, 2022	BUY	$4.6 - $9.91 $122,079 - $263,001	26,539 Added 93.57%	54,902 $0
Q2 2022 May 14, 2024	BUY	$3.72 - $9.0 $105,510 - $255,267	28,363 New	28,363 $130,000
Q2 2022 Aug 15, 2022	SELL	$3.72 - $9.0 $155,570 - $376,380	-41,820 Reduced 59.59%	28,363 $130,000
Q1 2022 May 16, 2022	SELL	$8.19 - $13.89 $383,709 - $650,760	-46,851 Reduced 40.03%	70,183 $607,000
Q4 2021 Feb 14, 2022	BUY	$12.98 - $29.75 $1.26 Million - $2.89 Million	97,266 Added 492.04%	117,034 $1.67 Million
Q3 2021 Nov 10, 2021	BUY	$12.13 - $23.82 $239,785 - $470,873	19,768 New	19,768 $435,000

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.